Browse by Journal Title

Article

Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced stage Hodgkin Lymphoma: results from the randomized international GHSG HD18 trial.
Ferdinandus, J. and Müller, H. and Damaschin, C. and Jacob, A.S. and Meissner, J. and Krasniqi, F. and Mey, U. and Schöndube, D. and Thiemer, J. and Mathas, S. and Zijlstra, J. and Greil, R. and Feuring-Buske, M. and Markova, J. and Rüffer, J.U. and Kobe, C. and Eich, H.T. and Baues, C. and Fuchs, M. and Borchmann, P. and Behringer, K.
Annals of Oncology 35 (3): 276-284. March 2023

Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies.
Rohr, U.P. and Herrmann, P. and Ilm, K. and Zhang, H. and Lohmann, S. and Reiser, A. and Muranyi, A. and Smith, J. and Burock, S. and Osterland, M. and Leith, K. and Singh, S. and Brunhoeber, P. and Bowermaster, R. and Tie, J. and Christie, M. and Wong, H.L. and Waring, P. and Shanmugam, K. and Gibbs, P. and Stein, U.
Annals of Oncology 28 (8): 1869-1875. 1 August 2017

SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study.
Sinn, M. and Sinn, B.V. and Striefler, J.K. and Lindner, J.L. and Stieler, J.M. and Lohneis, P. and Bischoff, S. and Blaeker, H. and Pelzer, U. and Neuhaus, P. and Dietel, M. and Doerken, B. and Oettle, H. and Riess, H. and Denkert, C.
Annals of Oncology 25 (5): 1025-1032. May 2014

Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma.
Meyer, A.H. and Stroux, A. and Lerch, K. and Eucker, J. and Eitle, J. and Hohloch, K. and Andrzejak, M. and Possinger, K. and Dörken, B. and Pezzutto, A. and Scholz, C.W.
Annals of Oncology 25 (1): 210-215. January 2014

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.
Hay, A.E. and Klimm, B. and Chen, B.E. and Goergen, H. and Shepherd, L.E. and Fuchs, M. and Gospodarowicz, M.K. and Borchmann, P. and Connors, J.M. and Markova, J. and Crump, M. and Lohri, A. and Winter, J.N. and Doerken, B. and Pearcey, R.G. and Diehl, V. and Horning, S.J. and Eich, H.T. and Engert, A. and Meyer, R.M.
Annals of Oncology 24 (12): 3065-3069. December 2013

Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort.
Schlesinger, S. and Aleksandrova, K. and Pischon, T. and Jenab, M. and Fedirko, V. and Trepo, E. and Overvad, K. and Roswall, N. and Tjønneland, A. and Boutron-Ruault, M.C. and Fagherazzi, G. and Racine, A. and Kaaks, R. and Grote, V.A. and Boeing, H. and Trichopoulou, A. and Pantzalis, M. and Kritikou, M. and Mattiello, A. and Sieri, S. and Sacerdote, C. and Palli, D. and Tumino, R. and Peeters, P.H. and Bueno-de-Mesquita, H.B. and Weiderpass, E. and Quirós, J.R. and Zamora-Ros, R. and Sánchez, M.J. and Arriola, L. and Ardanaz, E. and Tormo, M.J. and Nilsson, P. and Lindkvist, B. and Sund, M. and Rolandsson, O. and Khaw, K.T. and Wareham, N. and Travis, R.C. and Riboli, E. and Nöthlings, U.
Annals of Oncology 24 (9): 2449-2455. September 2013

NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia.
Terwey, T.H. and Le Duc, T.M. and Hemmati, P.G. and le Coutre, P. and Nagy, M. and Martus, P. and Doerken, B. and Arnold, R.
Annals of Oncology 24 (5): 1363-1370. May 2013

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Morschhauser, F. and Seymour, J.F. and Kluin-Nelemans, H.C. and Grigg, A. and Wolf, M. and Pfreundschuh, M. and Tilly, H. and Raemaekers, J. and van't Veer, M.B. and Milpied, N. and Cartron, G. and Pezzutto, A. and Spencer, A. and Reyes, F. and Dreyling, M.
Annals of Oncology 19 (2): 247-253. February 2008

Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.
Nickenig, C. and Dreyling, M. and Hoster, E. and Ludwig, W.D. and Doerken, B. and Freund, M. and Huber, C. and Ganser, A. and Truemper, L. and Forstpointner, R. and Unterhalt, M. and Hiddemann, W.
Annals of Oncology 18 (1): 136-142. January 2007

Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
Josting, A. and Rudolph, C. and Mapara, M. and Glossmann, J.P. and Sieniawski, M. and Sieber, M. and Kirchner, H.H. and Doerken, B. and Hossfeld, D.K. and Kisro, J. and Metzner, B. and Berdel, W.E. and Diehl, V. and Engert, A.
Annals of Oncology 16 : 116-123. 1 January 2005

High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
Josting, A. and Sieniawski, M. and Glossmann, J.P. and Staak, O. and Nogova, L. and Peters, N. and Mapara, M. and Doerken, B. and Ko, Y. and Metzner, B. and Kisro, J. and Diehl, V. and Engert, A.
Annals of Oncology 16 : 1359-1365. 1 January 2005

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
Josting, A. and Rudolph, C. and Reiser, M. and Mapara, M. and Sieber, M. and Kirchner, H.H. and Doerken, B. and Hossfeld, D.K. and Diehl, V. and Engert, A.
Annals of Oncology 13 (10): 1628-1635. October 2002

Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
Harstrick, A. and Kohne, C.H. and Hiddemann, W. and Preusser, P. and Strumberg, D. and Berns, T. and Seeber, S. and Wilke, H. and Schmoll, H.J.
Annals of Oncology 8 : 917-918. 1 September 1997

Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen.
Streit, M. and Jaehde, U. and Stremetzne, S. and Ridwelski, K. and Kerz, H. and Strohbach, F. and Hohenberger, P. and Zwiebel, F. and Hebart, H. and Boethig, R. and Kairies, M. and Zillig, D. and Schuchmann, S. and Warnecke, S. and Thiel, E. and Kreuser, E.
Annals of Oncology 8 : 1163-1165. 1 January 1997

Detection and management of advanced gastric cancer.
Hohenberger, P. and Huenerbein, M.
Annals of Oncology 7 : 197-203. 1 January 1996

Interferon-alpha does not improve the antineoplastic efficacy of highdose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer: First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO).
Koehne, C.H. and Wilke, H. and Hecker, H. and Schoeffski, P. and Kaeufer, C. and Rauschecker, H. and Andreesen, R. and Ohl, U. and Lange, H.J. and Klaassen, U. and Westerhausen, M. and Hiddemann, W. and Hennemann, B. and Schott, G. and Bade, J. and Strohmeyer, G. and Harstrick, A. and Schubert, U. and Bokemeyer, C. and Schmoll, H.J.
Annals of Oncology 6 : 461-466. 1 January 1995

Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF.
Engelhard, M. and Gerhartz, H. and Brittinger, G. and Engert, A. and Fuchs, R. and Geiseler, B. and Gerhartz, D. and Haunauske, A.R. and Hartlapp, H.J. and Huhn, D. and Ludwig, W.D. and Meusers, P. and Mueller, P. and Pees, H.W. and Peschel, C. and Radtke, H. and Schadeck-Gressel, C. and Schlimok, G. and Siegert, W. and Spann, W. and Terhardt, E. and Thiel, E. and Wilmanns, W. and Brandmaier, R. and Ehrlich, H.J. and Faerber, L. and Parwaresch, M. and Tiemann, M. and Lennert, K.
Annals of Oncology 5 Suppl. 2 : S 123-S 125. 1 January 1994

Adjuvant therapy for colon adenocarcinoma: current status of clinical investigation.
Koehne-Woempner, C. and Schoeffski, P. and Schmoll, H.J.
Annals of Oncology 5 Suppl. 3 : 97-104. 1 January 1994

Dose-escalating induction chemotherapy supported by lenograstim proceding high-dose consolidation chemotherapy for advanced breast cancer. Selection of the most acceptable regimen to induce maximal tumor response andinvestigation of the optimal time to collect peripheral blood progenitor cells for haematological rescue after high-dose consolidation chemotherapy.
van Hoef, A.H.A.M. and Baumann, I. and Lange, C. and Luft, T. and De Wynter, E.A. and Ranson, M. and Morgenstern, G.R. and Yvers, A. and Dexter, T.M. and Testa, N.G. and Howell, A.
Annals of Oncology 5 : 217-224. 1 January 1994